Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma - Hauschild, A; Agarwala, S S; Trefzer, U; Hogg, D; Robert, C; Hersey, P; Eggermont, A; Grabbe, S; Gonzalez, R; Gille, J; Peschel, C; Schadendorf, D; Garbe, C; O’Day, S; Daud, A; White, J M; Xia, C; Patel, K; Kirkwood, J M; Keilholz, U (J Clin Oncol, 2009)